COMMUNIQUÉS West-GlobeNewswire

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
25/09/2025
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that [...]
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
25/09/2025
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it [...]
Microbix Presenting at Muskoka Capital Event
25/09/2025
Meetings with Growth-Oriented Investors, September 26 to 28, 2025 MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, [...]
Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2026 Financial Results on October 9, 2025
25/09/2025
NEW YORK and LEAMINGTON, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
25/09/2025
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation NEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc [...]
Evaxion out-licenses vaccine candidate EVX-B3 to MSD
25/09/2025
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 [...]
Press release: Sequana Medical announces H1 2025 results and provides business update
25/09/2025
Sequana Medical announces H1 2025 results and provides business update alfapump ® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP “top-up” reimbursement; On track for at least 70 [...]
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
25/09/2025
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides the following update regarding its convertible bond announced on 23 September [...]
Les résultats semestriels confirment la pertinence de la stratégie de Roquette
25/09/2025
Les résultats semestriels confirment la pertinence de la stratégie de Roquette Roquette surperforme ses principaux marchés et enregistre des résultats solides au premier semestre dans des conditions de marché complexes [...]
Fagron announces the acquisition of UCP in North America and FDA inspection update
25/09/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of UCP in North America and FDA inspection update Fagron, the [...]
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
25/09/2025
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, [...]
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
25/09/2025
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go [...]
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
25/09/2025
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the “Company”) Co-development [...]
GUERBET : Mise à disposition du rapport financier semestriel 2025
25/09/2025
Mise à disposition du rapport financier semestriel 2025 Villepinte, le 25 septembre 2025 – Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce ce jour [...]
Summary Notice of Proposed Settlement of Derivative Actions
25/09/2025
LEHI, Utah, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Owlet, Inc. (NYSE:OWLT) has released the following notice: IN THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA IN RE OWLET, INC. SHAREHOLDER [...]
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
25/09/2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public [...]
H1 25 Results Confirm the Relevance of Roquette’s Strategy
25/09/2025
H1 25 Results Confirm the Relevance of Roquette’s Strategy Roquette outperforms its key markets, delivering solid H1 results in current complex market conditions. Successful completion of the acquisition of IFF Pharma [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]

Pages